Elucidate Tumor-Immune Interactions from a Single Sample

In the immuno-oncology era, it’s becoming clear that understanding and improving response to cancer immunotherapies and developing new compounds relies on the examination of the interactions between tumor cells and immune cells in the TME. Historically, gaining molecular insights into both the tumor and the immune system has necessitated the analysis of data derived from multiple sources, packaged in various formats. When samples are precious and limited, researchers need a way to both simplify this process and to maximize the data generated from each individual sample. This is where ImmunoID NeXT can help.

Figure 1: ImmunoID NeXT consolidates multiple biomarker assays into one; simultaneously solving many logistical and technical problems for clinical trial sponsors.

Broad Exploration of Modern Oncology Biomarkers

ImmunoID NeXT facilitates the identification of known and novel biomarkers that are predictive of resistance, response, and adverse event (AE) risk associated with modern oncology therapies. Click the appropriate biomarker category below to explore how ImmunoID NeXT can help you to evaluate relevant biomarkers of interest for each.

Resistance

Response

AE Risk

Composite

Despite the success of Immune Checkpoint Inhibitors (ICIs), the majority of initial non-responders tend to
progress at a natural rate, and a significant proportion of initial responders eventually relapse. Thus, understanding the underlying biological mechanisms of primary and acquired resistance to immunotherapy has become a major focus of the field. ImmunoID NeXT provides insight into the following known tumor escape mechanisms, while also aiding in the identification of previously-undefined ones:

Human Leukocyte Antigen (HLA)
Genomic alterations impacting HLA genes are common means by which tumors evade the host’s immune response, and exhibit resistance to immunotherapy. At Personalis, we’ve been pioneers in utilizing exome data and proprietary in silico methods to not only accurately genotype HLA genes, but also to reliably detect somatic mutations and loss of heterozygosity (LOH) events affecting these genes – alterations that can contribute directly to a tumor’s ability to circumvent the host’s immune system.
Antigen Processing Machinery (APM)
While the MHC proteins (which are encoded by HLA genes) are critical for the correct presentation of potentially-immunogenic antigens on the surface of tumor cells, defects occurring in any of the upstream components of the APM can also impact a cell’s ability to present such antigens for immunosurveillance.
Immune Checkpoint Modulation
Immune checkpoint inhibitors (ICIs) have transformed cancer care by antagonizing “checkpoint” proteins expressed on the surface of T-cells (CTLA-4 and PD-1) or by inhibiting the tumor-related ligands of these receptors (PD-L1). Based on this success, other methods of checkpoint modulation have been investigated such as targeting immunosuppressive enzymes (e.g. IDO), or activating immune effector cell receptors (e.g. OX40, 4-1BB), but these approaches have thus far been less fruitful, often due to the overexpression of immunosuppressive proteins in the TME.
Canonical Pathways
Somatic mutations occurring in genes associated with specific cancer- and/or immune-related pathways may influence the ability of tumor cells to evade the immune system. Alterations leading to the inactivation of canonical cancer pathways such as the MAPK and PI3K pathways are associated with increased resistance to ICIs, while activating mutations associated with the WNT-β-catenin and IDO1 pathways can result in the suppression of effector T-cells and NK cells in the TME (Conway et al., 2018).
Tumor Aneuploidy
Tumors with elevated numbers of somatic copy number alterations (CNAs) are susceptible to ICI resistance. It has been demonstrated that tumor aneuploidy can result in reduced expression of immune-related genes such as HLA, IFNγ pathway genes, chemokines, and cytolytic immune cell genes, conferring resistance in many cases (Keenan et al., 2019).
Cytokines/Chemokines
Unresponsiveness of tumor cells to reduced expression of interferon – particularly IFNγ, which is secreted by effector T-cells – is a common mechanism of resistance to immunotherapy. Additionally, there is a strong association between cytotoxic activity and the expression of genes involved in T-cell recruitment to the tumor site including interleukins and other cytokines. ImmunoID NeXT can be used to elucidate the TME phenotype and facilitate the discovery of novel cytokine/chemokine gene expression signatures of resistance to immunotherapies and combinations.
Tumor Surface Antigen Modulation
Surface antigen modulation is a well-understood escape mechanism for immunotherapies like chimeric antigen receptor (CAR)-T-cells, monoclonal antibodies, and bispecific T-cell engagers (BiTEs) that are commonly used to treat hematologic malignancies. While it can pre-exist therapy administration owing to inherent tumor heterogeneity, therapeutic pressure can induce alternative splicing; generating antigen isoforms with disruption of the target epitope and/or reduced cell surface expression (Shah & Fry, 2019).
Mechanisms of Resistance
CategoryImmunoID NeXT Solutions
Human Leukocyte Antigen
  • HLA Class I and Class II germline and tumor genotyping
  • HLA LOH
  • HLA somatic mutations
Antigen Processing Machinery
(Somatic mutations and gene expression)
  • B2M gene
  • TAP1/TAP2 genes
  • Proteasome-related genes
  • Endoplasmic reticulum-related genes
Immune Checkpoint Modulation
(Somatic mutations and gene expression)
  • Co-inhibitory targets (e.g. PD-L1/PD-1, CTLA-4, TIGIT, LAG-3, etc.)
  • Co-stimulatory targets (e.g. OX40, GITR, 4-1BB, CD40, etc.)
  • Immunosuppressive enzymes (e.g. IDO1/IDO2, ARG1, etc.)
Canonical Pathways
(Somatic mutations and gene expression)
  • JAK/STAT pathway
  • MAPK & PI3K pathways
  • WNT-β-catenin pathway
  • IDO1 pathway
  • And more…
Tumor Aneuploidy
  • Exome-wide CNA detection
Cytokines/Chemokines
(Somatic mutations and gene expression)
  • Type I and type II IFN-related genes
  • Interleukin genes
  • Other cytokine/chemokine genes involved in both innate and adaptive immunity
Tumor Surface Antigen Modulation
  • Transcript-specific expression (identification of alternatively-spliced variants)
  • Tumor surface antigen gene expression

Response

While understanding the reasons why certain patients are resistant to oncology therapies is important, it is even more critical to ensure that they are administered only to patients who are expected to respond. Therefore, the identification and use molecular markers that are predictive of response is imperative in bringing the curative potential of immuno-oncology drugs to more patients.

Neoantigen Load/Tumor Mutational Burden (TMB)
Despite the initial excitement surrounding the predictive potential of TMB as a biomarker of response, recent setbacks have called into question whether a simple count of non-synonymous somatic mutations is biologically informative enough to help guide treatment decisions. At Personalis, we believe that determining which of these mutations will be expressed as neoantigens and presented for immunosurveillance may be more indicative of a tumor’s potential susceptibility to immunotherapy.
Microsatellite Instability (MSI) Status
In 2017, MSI status became the first biomarker to be used in the FDA-approval of a cancer drug (Keytruda) for the treatment of advanced solid tumors based on a patient’s tumor biomarker status, rather than on tumor histology. This approval enabled clinicians to administer the drug to MSI-H patients; highlighting the clinical utility of MSI status as a predictive biomarker of immunotherapy response.
Immune Repertoire Profiling
Immune repertoire analysis has emerged as a major exploratory biomarker in predicting the likelihood of response to ICIs. Specifically, evaluating the clonality of the T-cell receptor (TCR) repertoire and identifying the most highly-expanded clonotypes in tumor samples have shown particular promise in this endeavor. With ImmunoID NeXT, it is now possible to characterize the immune repertoire using a broad content platform, and without the use of a separate, targeted immunosequencing kit, for which additional sample would be required.
Gene Expression Signatures
The inherent complexity of the tumor-immune interplay in the TME makes predicting response to immuno-oncology drugs exceptionally difficult. This has led to the increasingly-common evaluation of biomarkers that go beyond single genes and towards the analysis of more complex, multi-gene signatures. ImmunoID NeXT enables the assessment of all tumor- and/or immune-related genes and can facilitate the development of novel RNA expression signatures that may more effectively stratify responders from non-responders.
Predictive Biomarkers of Response
CategoryImmunoID NeXT Solutions
Neoantigen Load/Tumor Mutational Burden (TMB)
  • Neoantigen load
  • TMB
  • Synonymous and non-synonymous SNV and indel reporting
Microsatellite Instability (MSI) Status
  • Five canonical loci from the Updated Bethesda Consensus Panel
  • Proportion of all exome-wide MS-related loci found to be unstable
Immune Repertoire
  • TCRα chain repertoire profiling
  • TCRβ chain repertoire profiling
  • Characterization of clonality and top clonotypes
Gene Expression Signatures
  • Gene expression profiling of tumor- and/or immune-related genes
  • Advanced analysis for potential signature identification
Cancer-related Mutations
(SNVs, indels, fusions, and CNAs)
  • Validated exome-wide somatic variant detection at allelic fractions as low as 5%
  • Targeted panel-grade sensitivity/specificity across 247 clinically-relevant cancer driver genes
  • Neoantigen detection across all ~20,000 genes

AE Risk

For certain types of immunotherapies, the incidence of adverse events (AEs) such as cytokine release syndrome (CRS) and other immune-related AEs (irAEs) has served to temper excitement related to otherwise promising clinical outcomes. This has prompted the exploration of biomarkers that can be used to predict AE risk both before and during treatment.

Cytokine Expression Signatures
One emergent approach to predicting irAE risk (particularly CRS risk in CAR-T-treated patients) is cytokine gene expression profiling. Evaluating the pattern and timing of fluctuations in cytokine gene expression prior to and over the course of therapy can help to identify at-risk patients.
Germline Genetic Variations
Germline genetic factors can influence autoimmune disease risk. Since these diseases represent common irAEs associated with ICI therapy, it’s imperative to determine how to identify patients who are at risk of developing such complications. It has been shown that germline variants previously associated with autoimmune risk can potentially be used to evaluate susceptibility to irAEs in ICI-treated patients (Kirchhoff et al., 2017). Via germline variant reporting, ImmunoID NeXT can be leveraged to discover germline variants and variation signatures associated with AE risk.
Predictive Biomarkers of AE Risk
CategoryImmunoID NeXT Solutions
Cytokine expression signatures
  • Cytokine gene expression profiling
  • Inter-/intra-cohort differential gene expression analysis
Germline genetic variations
  • Germline variant analysis
Signature(s) identification
  • Advanced analysis for potential signature identification

Composite

The use of single-analyte biomarkers (e.g. PD-L1 expression) has yielded modest results in the quest to accurately predict which patients are likely to respond (or not) to immunotherapies and their combinations with other treatment modalities. In the immunotherapy age, it’s clear that more effective patient stratification techniques will require the integration of multiple biomarkers that not only molecularly profile a given patient’s tumor, but that also reveal how the host’s immune system is reacting to – and interacting with – that tumor.

At Personalis, we believe that such an approach will deliver the benefits of the immuno-oncology revolution to a greater proportion of patients. With the comprehensive tumor- and immune-related biomarker information that’s generated by the NeXT Platform, combined with our advanced, customizable, and integrative analytic capabilities, we can help our biopharmaceutical partners identify composite biomarkers to improve upon the predictive power of single-analyte approaches, and ultimately bring the benefits of immunotherapy to more cancer patients.